Table 1.
Baseline clinical and laboratory data and levels of serum Gd-IgA1 in 275 patients with IgAN
| Characteristics | Mean±SD (range or Percentage) |
|---|---|
| Age (year) | 32.7±10.7 (15–76) |
| Gender (Male) | 147/275 (53.5%) |
| SBP (mm Hg) | 124±16 |
| DBP (mm Hg) | 79±12 |
| Hypertension (%)a | 131/275 (47.6%) |
| Initial proteinuria (g/d) | 1.92±1.89 |
| <0.3(%) | 15/275(5.5%) |
| 0.3–0.99(%) | 84/275(30.5%) |
| 1.0–2.99(%) | 130/275(47.3%) |
| ≥3.0 | 46/275(16.7%) |
| eGFR (ml/min/1.73m2) | 82.65±27.44 |
| Stage 1,2,3,4CKD (K/DOQI)b | 125(45.7%),92(33.3%),50(18.0%),8(3%) |
| Follow-up interval (month, median, IQR) | 47 (30–60) |
| Gd-IgA1 (U/ml, median, IQR) | 312.5 (236.5–407.8) |
| Total IgA (ug/ml, median, IQR) | 2630.0 (2125.0–3510.0) |
| Plasma IgA1 (ug/ml, median, IQR) | 1709.9 (1376.2–2159.7) |
| Therapy (%) | |
| ACE inhibitors or ARBs | 96.7% |
| Prednisone | 46.2% |
| Any other immunosuppressive agents (cyclophosphamide, MMF or others) |
29.8% |
| Histological grading (%)c | |
| I, II, III, IV, V | 30(10.9%), 1(0.36%), 89(32.4%), 118(42.9%), 37(13.5%) |
Abbreviations: ACE, angiotensin-converting enzyme; ARB, angiotensin II receptor blocker; eGFR, estimate glomerular filtration rate; IQR, interquartile range
a
Hypertension was defined as systolic blood pressure of greater than 140 mm Hg, and/or diastolic blood pressure of greater than 90 mm Hg at resting, or use of anti-hypertension medication.
b
CKD stage 1, 2, 3, 4 were divided by eGFR ≥ 90, 60 to 89, 30 to 59, 15 to 29.
c
Histological grading was classified according to pathologic scheme proposed by Haas.45